- Home
- CDRE vs TSHA Comparison
CDRE vs TSHA Comparison
Compare CDRE & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDRE | TSHA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CDRE | TSHA |
|---|---|---|
| Price | $42.15 | $4.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $39.67 | $10.56 |
| AVG Volume (30 Days) | 170.7K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 62.50 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $567,561,000.00 | $8,333,000.00 |
| Revenue This Year | $12.51 | N/A |
| Revenue Next Year | $16.41 | N/A |
| P/E Ratio | $53.77 | ★ N/A |
| Revenue Growth | ★ 17.62 | N/A |
| 52 Week Low | $27.07 | $1.13 |
| 52 Week High | $46.64 | $6.02 |
Technical Indicators
Market Signals| Indicator | CDRE | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 55.57 |
| Support Level | $40.15 | $4.41 |
| Resistance Level | $44.37 | $5.39 |
| Average True Range (ATR) | 1.50 | 0.24 |
| MACD | 0.14 | 0.05 |
| Stochastic Oscillator | 53.19 | 96.55 |
Price Performance
Historical ComparisonAbout CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.